**Background**
Myocardial failure and acute heart failure represent critical clinical conditions characterized by the heart’s inability to pump sufficient blood to meet the metabolic demands of the body. A key therapeutic strategy for managing these conditions involves the use of positive inotropic agents to increase cardiac contractility and vasodilators to reduce systemic vascular resistance. The regulation of cyclic adenosine monophosphate (cAMP) plays a pivotal role in cardiac muscle contraction and vascular tone. By preventing the breakdown of cAMP, specific inhibitors can enhance heart function without relying on glycosides or catecholamines. In this context, we will introduce a selective phosphodiesterase III inhibitor – Amrinone.
**Definition**
Amrinone (Inamrinone) is a non-glycosidic and non-catecholamine cardiotonic agent that acts as a selective phosphodiesterase III inhibitor. According to the Amrinone description, it functions as a positive inotropic-vasodilator agent that increases intracellular levels of cyclic adenosine monophosphate by preventing its degradation.
**In Vitro and In Vivo Studies**
The Amrinone biological activity has been demonstrated across various experimental models. In vitro studies showed that Amrinone produced a dose-dependent inhibition of ADP-induced rat platelet aggregation both in vitro and ex vivo. Furthermore, the proliferation of human aortic smooth muscle cells stimulated with fetal bovine serum (FBS) or platelet-derived growth factor (PDGF) was inhibited by the compound. Regarding Amrinone In Vivo applications, the agent was administered subcutaneously to rats at a dose of 10 mg/kg/day for 14 days. This treatment resulted in a significant reduction of neointimal thickness following balloon injury. For researchers seeking specific Amrinone technical information, it is noted that the compound has a molecular weight of 187.20 and a chemical formula of C10H9N3O. In conclusion, Amrinone is a potent phosphodiesterase III inhibitor that serves as an effective tool for studying cardiac contractility and neointimal hyperplasia.
Keywords
Amrinone, 60719-84-8, Inamrinone, Phosphodiesterase (PDE), intractable, myocardial, failure, inotropic, cardiotonic, platelet, Inhibitor, inhibitor, inhibit
References
[1] M Hachisu, et al. [Effects of Amrinone, an Inhibitor of c-AMP-specific Phosphodiesterases, on Neointimal Hyperplasia After Balloon Injury in Rats]. Nihon Yakurigaku Zasshi. 1998 Oct;112(4):267-74.
[2] A A Alousi, et al. The Beneficial Effect of Amrinone on Acute Drug-Induced Heart Failure in the Anaesthetised Dog. Cardiovasc Res. 1985 Aug;19(8):483-94.
[3] S Ichioka, et al. Clinical Use of Amrinone (A Selective Phosphodiesterase III Inhibitor) in Reconstructive Surgery. Plast Reconstr Surg. 2001 Dec;108(7):1931-7.
[4] T H LeJemtel, et al. Amrinone: A New Non-Glycosidic, Non-Adrenergic Cardiotonic Agent Effective in the Treatment of Intractable Myocardial Failure in Man. Circulation. 1979 Jun;59(6):1098-104.